What is the purpose of HUTCHMED’s 2026 Share Option Scheme?

The 2026 Share Option Scheme allows HUTCHMED to grant share options over up to 43,616,756 ordinary shares. It is designed to provide equity-based incentives, with shares issued upon exercise and ranking pari passu with existing ordinary shares.

What happens to HUTCHMED’s previous 2015 share option scheme block admission?

The existing block admission related to the 2015 share option scheme, covering 45,768,368 ordinary shares, remains in effect. It continues to provide capacity for issuing shares under that earlier scheme alongside the new 2026 scheme block admission.

HUTCHMED seeks AIM block admission for options

HUTCHMED (China) Limited has applied to the London Stock Exchange for a block admission of 43,616,756 ordinary shares, each with a par value of US$0.10, to be admitted to trading on AIM in connection with its 2026 Share Option Scheme.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

HUTCHMED (China) Limited has applied to the London Stock Exchange for a block admission of 43,616,756 ordinary shares, each with a par value of US$0.10, to be admitted to trading on AIM in connection with its 2026 Share Option Scheme. Admission is expected to become effective on June 11, 2026. These shares may be issued over time upon exercise of options granted under the scheme and will rank equally with existing ordinary shares. Following admission, the Company’s total issued share capital remains 872,335,120 ordinary shares, each carrying one voting right, with no shares held in treasury. An existing block admission of 45,768,368 ordinary shares relating to a 2015 share option scheme also remains in effect.

Key Figures

Block admission size: 43,616,756 ordinary shares Par value per share: US$0.10 per ordinary share Total issued share capital: 872,335,120 ordinary shares +4 more

7 metrics

Block admission size 43,616,756 ordinary shares Applied for admission to trading on AIM for 2026 Share Option Scheme

Par value per share US$0.10 per ordinary share Par value of shares covered by the block admission

Total issued share capital 872,335,120 ordinary shares Total issued share capital following admission, each with one voting right

Existing block admission 45,768,368 ordinary shares Remaining block admission for 2015 share option scheme

Expected admission date June 11, 2026 Date admission of the new block on AIM is expected to become effective

AGM approval date May 12, 2026 Date shareholders approved the 2026 Share Option Scheme

Block utilisation reporting Six-monthly Frequency of utilisation announcements under AIM Rule 29

Key Terms

block admission, Share Option Scheme, AIM Rule 29, par value, +1 more

5 terms

block admission regulatory

"an application has been made to the London Stock Exchange plc for a block admission of 43,616,756 ordinary shares"

AIM Rule 29 regulatory

"The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29"

par value financial

"43,616,756 ordinary shares, par value of US$0.10 each"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

voting rights financial

"total issued share capital of the Company remains unchanged at 872,335,120 Ordinary Shares, with each share carrying one right to vote"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HUTCHMED (HCM) announce in this Form 6-K?

HUTCHMED announced an application for a block admission of 43,616,756 ordinary shares to be admitted to trading on AIM. These shares relate to its 2026 Share Option Scheme and may be issued over time when employees exercise share options.

How many HUTCHMED shares are covered by the new block admission?

The block admission covers 43,616,756 ordinary shares with a par value of US$0.10 each. These shares are reserved to satisfy exercises under the 2026 Share Option Scheme approved at the May 12, 2026 annual general meeting.

Does the HUTCHMED block admission change the total shares in issue?

The total issued share capital remains 872,335,120 ordinary shares following admission. The block admission only creates capacity for future option exercises; it does not itself issue new shares or alter the current number in circulation.

When will the HUTCHMED block admission on AIM become effective?

The admission of 43,616,756 ordinary shares to trading on AIM is expected to become effective on June 11, 2026. The shares will be issued from time to time as options under the 2026 Share Option Scheme are exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/05/2026 - 06:04 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of June 2026

Commission File Number: 001-37710

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX


Exhibit No.		Description

Exhibit 99.1		Announcement relating to block admission application

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	HUTCHMED (CHINA) LIMITED


	By:	/s/ Johnny Cheng
	Name:	Johnny Cheng
	Title:	Chief Financial Officer

Date: June 5, 2026

Exhibit 99.1

Block Admission Application

Hong Kong, Shanghai & Florham Park, NJ — Friday, June 5, 2026: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) today announces an application has been made to the London Stock Exchange plc for a block admission of 43,616,756 ordinary shares, par value of US$0.10 each (“Ordinary Shares”) to be admitted to trading on AIM. It is expected that such admission will become effective on June 11, 2026.

These Ordinary Shares will be issued from time to time pursuant to the exercise of share options under the Share Option Scheme adopted by the Company in 2026 (“2026 Share Option Scheme”). When issued, these Ordinary Shares will be credited as fully paid and will rank pari passu with the existing Ordinary Shares in issue. The Company is seeking this block admission due to the adoption of the 2026 Share Option Scheme, as approved at its annual general meeting held on May 12, 2026 (“AGM”), whereby the Company was empowered to grant options under that scheme in respect of a maximum of 43,616,756 Ordinary Shares. Following admission, the total issued share capital of the Company remains unchanged at 872,335,120 Ordinary Shares, with each share carrying one right to vote and with no shares held in treasury. The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29 and monthly announcements as to any changes to its total voting rights.

The balance of the existing block admission in respect of the Company’s previous share option scheme adopted in 2015 of 45,768,368 Ordinary Shares (the “Existing Block Admission”) remains in effect.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com

Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500

Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500

Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

EX-99 EX-99 14.7 KB